Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
22 November 2017

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Lupin Ltd (Pharmaceuticals - Indian - Bulk Drugs)

Last Price 833.50
Net Changes -3.95
Volume 688413
Prev Close 837.45
833.50 -3.95 (-0.47%)
Date: Nov 22,2017 10:59:59




Index Details Pharmaceuticals - Indian - Bulk Drugs


Chart

Stock Price Details

Market Statistics

Open Price 838.05 Div Yield (%) 0.89
Buy (Size) 832.85(×180) Eps(Rs) 47.61
Sell (Size) 833.45(×60) Book Value(Rs) 335.5473708
Buy Quantity 180 Market Cap(Rs.Cr) 37854.42
Sell Quantity 60 Face Value(Rs) 2
Today's High 842 Market Lot 1
Today's Low 830.1 AGM Date Aug
52-Week High 1572.25 Book Closure Date Jul/Aug
52-Week Low 818.55 ISIN No. INE326A01037

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 803800 0.18
Indian (Promoter & Group) 210675730 46.63
Total of Promoter 211479530 46.80
Non Promoter (Institution) 181004558 40.06
Non Promoter (Non-Institution) 59354038 13.14
Total Non Promoter 240358596 53.20
Total Promoter & Non Promoter 451838126 100.00
Custodians(Against Depository Receipts) 0 0.00
Grand Total 451838126 100.00

Company News

08-Nov-2017  Other announcement of Lupin Ltd
Other announcement of Lupin Ltd

Intimation regarding Investors call.
08-Nov-2017  Lupin Limited - LupinAnalysts/Institutional Investor Meet/Con....
Lupin Limited - LupinAnalysts/Institutional Investor Meet/Con. Call Updatesn

Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
07-Nov-2017  Lupin nosedives after USFDA issues warning letters for Goa & I...
Lupin nosedives after USFDA issues warning letters for Goa & Indore sites

The announcement was made during market hours today, 7 November 2017.

Meanwhile, the S&P BSE Sensex was down 341.41 points or 1.01% at 33,389.78.

High volumes were witnessed on the counter. On the BSE, 21.34 lakh shares were traded on the counter so far as against the average daily volumes of 1.36 lakh shares in the past two weeks. The stock had hit a low of Rs 851.20 so far during the day, which is also a 52-week low for the stock. The stock had hit a high of Rs 1,044 in intraday trade. The stock had hit a 52-week high of Rs 1,572.25 on 6 February 2017.

The stock had underperformed the market over the past one month till 6 November 2017, falling 0.73% compared with 6.03% gains in the Sensex. The scrip had also underperformed the market in the past one quarter, rising 4.25% as against Sensex's 4.35% rise. The scrip had also underperformed the market in the past one year, dropping 27.18% as against Sensex's 23.67% rise.

The large-cap company has equity capital of Rs 90.38 crore. Face value per share is Rs 2.

Lupin said that the company has received warning letter issued by the United States Food & Drug Administration (USFDA) yesterday, 6 November 2017, for the company's formulation manufacturing facilities at Goa and Indore, Pithampur II.

The company had responded to all the observations after earlier receiving 3 Form 483 observations in Goa on 7 April 2017 and 6 Form 483 observations in Pithampur Unit II on 19 May 2017.

The company said that it is deeply disappointed to have received the current outcome. While there will be no disruption of existing product supplies from either of these locations, there will likely to be a delay of new product approvals from these two facilities.

The company said that it upholds quality and compliance issues with utmost seriousness and remains fully committed to be compliant with cGMP quality standards across all its facilities. The company plans to address the concerns raised by the USFDA expeditiously and will work with the USFDA to resolve these issues at the earliest.

Lupin's consolidated net profit fell 31.3% to Rs 455.01 crore on 8% decline in net sales to Rs 3874.16 crore in Q2 September 2017 over Q2 September 2016.

Lupin is a transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

07-Nov-2017  Other announcement of Lupin Ltd
Other announcement of Lupin Ltd

Combined Warning letter issued by USFDA for Company's Goa and Indore (Pithampur Unit II) sites.
07-Nov-2017  Lupin Limited - Analysts/Institutional Investor Meet/Con. Call...
Lupin Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Lupin Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates
07-Nov-2017  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated November 07, 2017, titled 'Combined Warning Letter issued by USFDA for Company;'s Goa and Indore (Pithampur Unit II) sites'.
03-Nov-2017  Lupin Limited - Press Release
Lupin Limited - Press Release

Lupin Limited has informed the Exchange regarding a press release dated November 02, 2017, titled 'Lupin launches generic Acticlate. Tablets in the US'.
02-Nov-2017  Other announcement of Lupin Ltd
Other announcement of Lupin Ltd

Lupin launches generic Acticlater Tablets in the US.
31-Oct-2017  Lupin standalone net profit declines 40.45% in the September 2...
Lupin standalone net profit declines 40.45% in the September 2017 quarter

Net profit of Lupin declined 40.45% to Rs 388.90 crore in the quarter ended September 2017 as against Rs 653.08 crore during the previous quarter ended September 2016. Sales declined 12.10% to Rs 2528.11 crore in the quarter ended September 2017 as against Rs 2876.21 crore during the previous quarter ended September 2016.

ParticularsQuarter Ended
 Sep. 2017Sep. 2016% Var.
Sales2528.112876.21 -12
OPM %21.4231.51 -
PBDT605.20921.95 -34
PBT509.82835.54 -39
NP388.90653.08 -40
31-Oct-2017  Lupin consolidated net profit declines 31.29% in the September...
Lupin consolidated net profit declines 31.29% in the September 2017 quarter

Net profit of Lupin declined 31.29% to Rs 455.01 crore in the quarter ended September 2017 as against Rs 662.19 crore during the previous quarter ended September 2016. Sales declined 8.00% to Rs 3874.16 crore in the quarter ended September 2017 as against Rs 4211.18 crore during the previous quarter ended September 2016.

ParticularsQuarter Ended
 Sep. 2017Sep. 2016% Var.
Sales3874.164211.18 -8
OPM %22.0224.47 -
PBDT883.111033.09 -15
PBT610.93821.90 -26
NP455.01662.19 -31
Incorporation Year 1983 
Registered Office Kalpataru Inspire 3rd Floor,Off Western Exp HW Santacruz-E,
,
Maharashtra-400055
Telephone 91-22-6640 2323 
Fax 91-22-6640 8131 
Chairman D B Gupta
Managing Director Nilesh Gupta
Company Secretary R V Satam 
Auditor B S R & Co LLP 
Face Value(Rs)
Market Lot
Listing MCX-SX,BSE,NSE 
Registrar Lupin Ltd
Kalpataru Inspire,3rd Floor,Santacruz (East),Mumbai - 400 055 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS